• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VEGFR-3的免疫表达与下唇鳞状细胞癌的转移相关,而VEGF-C的免疫表达或淋巴管密度则与之无关。

Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.

作者信息

de Aquino A R L, Nonaka C F W, de Carvalho C H P, Demeda C F, de Souza L B, Pinto L P

机构信息

Dentistry Department, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.

Dentistry Department, State University of Paraíba, Campina Grande, Paraíba, Brazil.

出版信息

Int J Oral Maxillofac Surg. 2017 Jan;46(1):16-23. doi: 10.1016/j.ijom.2016.09.012. Epub 2016 Oct 11.

DOI:10.1016/j.ijom.2016.09.012
PMID:27745792
Abstract

The purpose of this study was to evaluate the immunoexpression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor 3 (VEGFR-3) and their correlation with intratumoural lymphatic density (ILD) and peritumoural lymphatic density (PLD) in metastatic and non-metastatic lower lip squamous cell carcinoma (LLSCC). Twenty-five LLSCC with regional nodal metastasis and 25 LLSCC without metastasis were selected. The percentages of VEGF-C and VEGFR-3 staining in each tumour core and at the deep invasive front were assessed. PLD and ILD were determined using anti-podoplanin antibody. Immunohistochemical findings were correlated with nodal metastasis, clinical staging, local recurrence, clinical outcome, and histological grade. Cytoplasmic immunoexpression of VEGFR-3 in the tumour core was associated with metastasis (P=0.009), patient death (P=0.008), and histological grade (P<0.005). PLD, ILD, and VEGF-C expression showed no significant associations with clinicopathological parameters (P>0.05). PLD and ILD were not significantly correlated with the immunoexpression of VEGF-C or VEGFR-3 (P>0.05). There was a significant positive correlation between PLD and ILD (P=0.004), and between cytoplasmic immunoreactivity of VEGF-C and VEGFR-3 (P=0.011). These results suggest an important role for VEGFR-3 in the progression of LLSCC, and highlight the possible influence of its expression on the prognosis of these tumours. ILD and PLD may not be associated with lymph node metastasis in LLSCC.

摘要

本研究旨在评估血管内皮生长因子C(VEGF-C)和VEGF受体3(VEGFR-3)的免疫表达及其与转移性和非转移性下唇鳞状细胞癌(LLSCC)的肿瘤内淋巴管密度(ILD)和肿瘤周围淋巴管密度(PLD)的相关性。选取了25例伴有区域淋巴结转移的LLSCC和25例无转移的LLSCC。评估了每个肿瘤核心及深部浸润前沿中VEGF-C和VEGFR-3染色的百分比。使用抗足突蛋白抗体测定PLD和ILD。免疫组化结果与淋巴结转移、临床分期、局部复发、临床结局及组织学分级相关。肿瘤核心中VEGFR-3的细胞质免疫表达与转移(P=0.009)、患者死亡(P=0.008)及组织学分级(P<0.005)相关。PLD、ILD和VEGF-C表达与临床病理参数无显著相关性(P>0.05)。PLD和ILD与VEGF-C或VEGFR-3的免疫表达无显著相关性(P>0.05)。PLD与ILD之间(P=0.004)以及VEGF-C与VEGFR-3的细胞质免疫反应性之间(P=0.011)存在显著正相关。这些结果表明VEGFR-3在LLSCC进展中起重要作用,并突出了其表达对这些肿瘤预后的可能影响。ILD和PLD可能与LLSCC的淋巴结转移无关。

相似文献

1
Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.VEGFR-3的免疫表达与下唇鳞状细胞癌的转移相关,而VEGF-C的免疫表达或淋巴管密度则与之无关。
Int J Oral Maxillofac Surg. 2017 Jan;46(1):16-23. doi: 10.1016/j.ijom.2016.09.012. Epub 2016 Oct 11.
2
Participation of hypoxia-inducible factor-1α and lymphangiogenesis in metastatic and non-metastatic lower lip squamous cell carcinoma.缺氧诱导因子-1α 与淋巴管生成在转移性和非转移性下唇鳞状细胞癌中的作用。
J Craniomaxillofac Surg. 2018 Oct;46(10):1741-1747. doi: 10.1016/j.jcms.2018.07.020. Epub 2018 Jul 29.
3
[Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].血管内皮生长因子C及血管内皮生长因子受体3在非小细胞肺癌中的表达及临床意义
Ai Zheng. 2005 Sep;24(9):1132-5.
4
Immunoexpression of human leukocyte antigen-DR in actinic cheilitis and lower lip squamous cell carcinoma.人白细胞抗原-DR在光化性唇炎及下唇鳞状细胞癌中的免疫表达
Braz Oral Res. 2019 Aug 29;33:e085. doi: 10.1590/1807-3107bor-2019.vol33.0085.
5
[Correlation of lymphangiogenesis to progression of colorectal cancer].[淋巴管生成与结直肠癌进展的相关性]
Ai Zheng. 2005 Oct;24(10):1276-9.
6
Expression of glucose transporters 1 and 3 in metastatic and non-metastatic lower lip squamous cell carcinoma.葡萄糖转运蛋白1和3在转移性及非转移性下唇鳞状细胞癌中的表达
Braz Dent J. 2014 Sep-Oct;25(5):372-8. doi: 10.1590/0103-6440201300054.
7
Tumour expression of lymphangiogenic growth factors but not lymphatic vessel density is implicated in human cervical cancer progression.肿瘤中淋巴管生成生长因子的表达而非淋巴管密度与宫颈癌的进展相关。
Pathology. 2010 Dec;42(7):629-36. doi: 10.3109/00313025.2010.522174.
8
Cyclo-oxygenase-2 expression is associated with vascular endothelial growth factor C expression and lymph node metastasis in oral squamous cell carcinoma.环氧化酶-2的表达与口腔鳞状细胞癌中血管内皮生长因子C的表达及淋巴结转移相关。
J Oral Maxillofac Surg. 2013 Oct;71(10):1694-702. doi: 10.1016/j.joms.2013.04.015. Epub 2013 Jul 1.
9
Twist modulates lymphangiogenesis and correlates with lymph node metastasis in supraglottic carcinoma.Twist 调节淋巴管生成并与声门上型癌的淋巴结转移相关。
Chin Med J (Engl). 2011 May;124(10):1483-7.
10
[Expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and nm23-H1 in oral squamous cell carcinoma].[血管内皮生长因子、血管内皮生长因子受体-3及nm23-H1在口腔鳞状细胞癌中的表达]
Zhonghua Kou Qiang Yi Xue Za Zhi. 2007 Nov;42(11):681-3.

引用本文的文献

1
The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.血管内皮生长因子受体-3 在胃癌中的病理作用及潜在机制。
J Int Med Res. 2024 Mar;52(3):3000605241234558. doi: 10.1177/03000605241234558.
2
Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review.血管生成标志物在头颈部鳞状细胞癌中的诊断、预后和治疗作用:叙述性综述。
Int J Mol Sci. 2023 Jun 27;24(13):10733. doi: 10.3390/ijms241310733.
3
Correlation among gene promoter methylation, protein overexpression, and clinical pathology in early gastric cancer.
早期胃癌中基因启动子甲基化、蛋白过表达与临床病理之间的相关性
Transl Cancer Res. 2020 May;9(5):3499-3506. doi: 10.21037/tcr.2020.03.74.